Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2023-47797
Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Description
Reflected cross-site scripting (XSS) vulnerability on a content page’s edit page in Liferay Portal 7.4.3.94 through 7.4.3.95 allows remote attackers to inject arbitrary web script or HTML via the `p_l_back_url_title` parameter.
Source: NVD (National Vulnerability Database)
CVSS Information
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:H
Source: NVD (National Vulnerability Database)
Vulnerability Type
在Web页面生成时对输入的转义处理不恰当(跨站脚本)
Source: NVD (National Vulnerability Database)
Vulnerability Title
Liferay Portal 安全漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
Liferay Portal是美国Liferay公司的一套基于J2EE的门户解决方案。该方案使用了EJB以及JMS等技术,并可作为Web发布和共享工作区、企业协作平台、社交网络等。 Liferay Portal 7.4.3.94至7.4.3.95版本存在安全漏洞,该漏洞源于存在反射型跨站脚本(XSS)漏洞。攻击者可利用该漏洞通过p_l_back_url_title参数注入任意web脚本或HTML代码。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
LiferayPortal 7.4.3.94 ~ 7.4.3.95 -
II. Public POCs for CVE-2023-47797
#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2023-47797
Please Login to view more intelligence information
IV. Related Vulnerabilities
V. Comments for CVE-2023-47797

No comments yet


Leave a comment